Ruichen Li, Qi Wang, Siyuan Ma, Ji Li, Yang Zhao, Xiaoshen Wang
{"title":"The association between level IV/V metastasis and the recurrence, distant metastasis, and survival outcomes in hypopharyngeal squamous cell carcinoma.","authors":"Ruichen Li, Qi Wang, Siyuan Ma, Ji Li, Yang Zhao, Xiaoshen Wang","doi":"10.1177/17588359241312079","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The presence of level IV/V metastasis is a significant prognostic factor for patients with oral and oropharyngeal cancer, while level IV lymphadenopathy defines the N3 stage in nasopharyngeal carcinoma. However, the current staging system for hypopharyngeal squamous cell carcinoma (HPSCC) does not consider the location of involved nodes.</p><p><strong>Objectives: </strong>To evaluate the risk factors and prognostic impact of level IV/V metastasis in patients with HPSCC.</p><p><strong>Methods: </strong>The analysis included 2740 HPSCC patients from the SEER (Surveillance, Epidemiology, and End Results) database, followed by a validated study on 232 patients with pathologically positive nodes (pN+) at our center.</p><p><strong>Results: </strong>Of the 2740 patients, 1961 presented with metastatic lymph nodes (LNs), 20.8% and 14.1% had nodal involvement in level IV and level V, respectively. Multivariate analysis revealed that N3 and M1 stages were independently associated with level IV/V metastasis. Level IV metastasis was the sole independent adverse factor for overall survival (OS) among all LN regions (<i>p</i> < 0.05). Regarding cancer-specific survival (CSS), only level IV and V involvement were independent predictors of prognosis (<i>p</i> < 0.05). The rate of pN+ at levels IV and V in our center was 35.8% and 16.4%, respectively. The advanced pN stage was independently associated with metastasis to level IV or V. Patients with level IV/V metastasis had significantly higher rates of regional recurrence and distant metastases (<i>p</i> < 0.001). Multivariate analysis confirmed a significant association regarding OS, CSS, locoregional relapse-free survival (LRFS), or distant metastasis-free survival between patients with and without level IV metastasis (<i>p</i> < 0.05). Patients with level IV/V disease exhibited decreased survival rates across stages pN1 to pN3. Postoperative chemoradiotherapy improved LRFS in patients with level IV lymphadenopathy and OS/CSS in patients with level V metastasis.</p><p><strong>Conclusion: </strong>Metastasis to level IV/V was associated with a worse prognosis in HPSCC patients. The level IV/V should be considered for future improvements to the staging system.</p><p><strong>Design: </strong>A retrospective study.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359241312079"},"PeriodicalIF":4.2000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11760138/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17588359241312079","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The presence of level IV/V metastasis is a significant prognostic factor for patients with oral and oropharyngeal cancer, while level IV lymphadenopathy defines the N3 stage in nasopharyngeal carcinoma. However, the current staging system for hypopharyngeal squamous cell carcinoma (HPSCC) does not consider the location of involved nodes.
Objectives: To evaluate the risk factors and prognostic impact of level IV/V metastasis in patients with HPSCC.
Methods: The analysis included 2740 HPSCC patients from the SEER (Surveillance, Epidemiology, and End Results) database, followed by a validated study on 232 patients with pathologically positive nodes (pN+) at our center.
Results: Of the 2740 patients, 1961 presented with metastatic lymph nodes (LNs), 20.8% and 14.1% had nodal involvement in level IV and level V, respectively. Multivariate analysis revealed that N3 and M1 stages were independently associated with level IV/V metastasis. Level IV metastasis was the sole independent adverse factor for overall survival (OS) among all LN regions (p < 0.05). Regarding cancer-specific survival (CSS), only level IV and V involvement were independent predictors of prognosis (p < 0.05). The rate of pN+ at levels IV and V in our center was 35.8% and 16.4%, respectively. The advanced pN stage was independently associated with metastasis to level IV or V. Patients with level IV/V metastasis had significantly higher rates of regional recurrence and distant metastases (p < 0.001). Multivariate analysis confirmed a significant association regarding OS, CSS, locoregional relapse-free survival (LRFS), or distant metastasis-free survival between patients with and without level IV metastasis (p < 0.05). Patients with level IV/V disease exhibited decreased survival rates across stages pN1 to pN3. Postoperative chemoradiotherapy improved LRFS in patients with level IV lymphadenopathy and OS/CSS in patients with level V metastasis.
Conclusion: Metastasis to level IV/V was associated with a worse prognosis in HPSCC patients. The level IV/V should be considered for future improvements to the staging system.
背景:IV级/V级转移是口腔癌和口咽癌患者预后的重要因素,而IV级淋巴结病变定义了鼻咽癌的N3期。然而,目前的下咽鳞状细胞癌(HPSCC)分期系统没有考虑受病灶淋巴结的位置。目的:探讨人乳头状瘤细胞癌IV/V级转移的危险因素及对预后的影响。方法:分析了来自SEER(监测、流行病学和最终结果)数据库的2740例HPSCC患者,随后对我们中心232例病理阳性淋巴结(pN+)患者进行了验证研究。结果:2740例患者中,1961例出现转移性淋巴结(LNs),其中20.8%和14.1%分别为IV级和V级淋巴结累及。多变量分析显示N3期和M1期与IV/V级转移独立相关。在所有LN区域中,IV级转移是影响总生存(OS)的唯一独立不利因素(p p p p)结论:转移到IV/V级与HPSCC患者预后较差相关。IV/V级应该被考虑用于将来对分级系统的改进。设计:回顾性研究。
期刊介绍:
Therapeutic Advances in Medical Oncology is an open access, peer-reviewed journal delivering the highest quality articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in medical oncology, providing a forum in print and online for publishing the highest quality articles in this area. This journal is a member of the Committee on Publication Ethics (COPE).